Smart contact lenses market seen reaching $10.72M by 2035

Market Research Future projects the global smart contact lenses market will grow from $5.91 million in 2026 to $10.72 million by 2035, driven by biosensor miniaturization, reimbursement expansion and low-power connectivity. The forecast points to stronger adoption in glaucoma monitoring, hospital use and Asia-Pacific manufacturing.

Why it matters: - Smart contact lenses are moving from experimental wearables toward reimbursable clinical tools for glaucoma, glucose monitoring and other chronic conditions. - The projected growth reflects a shift away from consumer novelty use and toward hospital, clinic and home-monitoring workflows. - The market's expansion could affect ophthalmology care, digital therapeutics spending and connected health infrastructure through 2035.

What happened: - Market Research Future said the global smart contact lenses market is projected to rise from USD 5.91 million in 2026 to USD 10.72 million by 2035. - The forecast implies a 6.85% CAGR during 2026–2035. - The market base was estimated at USD 5.50 million in 2025. - The report pointed to sub-microwatt biosensor miniaturization, reimbursement code expansion and 5G/LTE-M connectivity as the main growth drivers. - The company offered a free sample and detailed report access.

The details: - Power consumption below 1 microwatt is described as the threshold for 24-hour continuous wear. - Stanford's Byers Center for Biodesign demonstrated a 0.3 µW tear-glucose sensor in late 2023 that operated for 18 hours on a thin-film supercapacitor harvesting blink energy. - The report says that breakthrough cut the minimum viable sensor footprint from 1.2 mm² to 0.6 mm². - That smaller footprint allows two analyte channels, glucose and intraocular pressure, on one substrate without reducing oxygen permeability. - The report assigns sub-microwatt sensor miniaturization an 18% impact on CAGR. - CMS introduced two Category III CPT codes for continuous intraocular pressure monitoring via smart lenses in January 2025. - Germany's Federal Joint Committee issued a positive health technology assessment for tear-based glaucoma screening in March 2025. - The report says reimbursement timing has historically tracked ophthalmology adoption within 18–24 months of code publication. - Low-power wide-area network protocols, including LTE-M and NB-IoT, are presented as the fix for latency issues that limited earlier Bluetooth-only lenses. - SK Telecom's partnership with a Seoul-based lens developer achieved sub-200 millisecond transmission from lens to cloud in 2024 field trials at three Korean hospitals. - The report estimates 14% of CAGR impact from 5G and LTE-M integration. - In application terms, ocular monitoring and glaucoma treatment held 54.5% of revenue in 2025. - The report ties that segment to an estimated 80 million global glaucoma patients and piezoresistive sensors that detect intraocular pressure changes within ±0.5 mmHg. - Vision impairment is projected to grow at 8.25% CAGR through 2035 as electronically adjustable focal-length lenses mature. - Prototype lenses shown at ARVO 2024 adjusted real-time diopters across a –6.0 to +3.0 range using liquid-crystal optical elements. - Hospitals and ophthalmology clinics were the largest end-user segment in 2025 with a 42.7% share. - Home-care and self-monitoring consumers were the fastest-growing end-user segment, projected at 8.52% CAGR. - The report listed research institutions and military users at USD 0.47 million in 2025. - North America led the market with about 54.4% share in 2025. - The U.S. accounted for roughly 78.2% of North American revenue, helped by NIH funding of USD 48 million for wearable ocular diagnostics research from 2023 to 2026. - Europe ranked second with 23.1% share in 2025, supported by the EU MDR Class IIa framework. - Asia-Pacific was the fastest-growing region at 7.61% CAGR, with South Korea's contract manufacturers cited for 35% to 40% lower precision micro-assembly costs than North American equivalents. - China held 31.5% of Asia-Pacific share, and Japan held 26.8%. - South America's adoption was led by Brazil, which accounted for 62.1% of regional revenue. - In the Middle East and Africa, Saudi Arabia led with 33.8% of regional share. - The competitive landscape was described as medium concentration, with the top five players controlling an estimated 38% to 46% of global revenue. - Sensimed SA was cited as a first mover in CE-marked continuous IOP monitoring. - Verily Life Sciences was listed for tear-glucose biosensing with AI and machine learning analytics. - Mojo Vision, Novartis, Johnson & Johnson Vision, Samsung Electronics, Sony Group, Alcon, InWith Corporation and Medella Health were also named among key companies.

Between the lines: - The forecast suggests reimbursement and hospital procurement matter more than consumer demand in determining near-term growth. - The report frames smart lenses as part of a broader move toward connected disease management, not just vision correction. - Regional adoption appears to depend heavily on health-system coverage, regulatory pathways and local manufacturing capacity. - The market still looks early-stage, with revenue concentrated in a few clinical use cases and a relatively small group of leading players.

What's next: - The report expects AI-driven predictive diagnostics to become a major differentiator in the early 2030s. - It says machine learning could flag glaucoma risk 48 to 72 hours before intraocular pressure spikes become clinically significant. - Device-as-a-service subscription models are expected to gain traction as vendors bundle hardware, cloud analytics and clinician dashboards. - Smart lenses are also expected to connect more deeply with patches, implantable sensors and electronic health records. - EU sustainability rules could push manufacturers toward recyclable electronics, biodegradable substrates and take-back programs later in the decade.

The bottom line: - Smart contact lenses remain a niche market, but the combination of reimbursement, miniaturized sensors and low-latency connectivity is setting up a longer-term shift from prototype wearables to clinical infrastructure.